Three perspectives on technology evolution

Richard Hamilton Gibbs, Steven W. Fowkes, Tom Nufert



When:    Tuesday, October 14th, 6:30 - 9:00 pm 

Where:   Fenwick & West, 801 California St., Mountain View, CA 

RSVP:     http://www.jhtc.org



Regular Admission: $10    

Student Admission: $5  (ID required)

Members Admission: Included (Join at http://jhtc.org)



Agenda

6:30 - 7:00:  Networking, schmoozing and eating - Bring your job postings,

business cards and resumes!

7:00 - 7:10:  Welcome, committee news and other group business

7:10 - 8:30:  Presentation and Discussion with our featured guests

8:30 - 9:00:  Informal discussions and networking with our guests and each

other



A light meal and soft drinks will be provided



About the Speakers

Richard Hamilton Gibbs is an entrepreneur in the computer, computer

peripheral, media and home entertainment markets currently researching how

technological advances are affecting distribution models for music and

movies and how adherence to traditional models are damaging the

profitability of mainstream entertainment businesses, sabotaging revenues

for artists, and alienating consumers based on competition between

proprietary and non-proprietary platforms.



Steven W. Fowkes is the Director of the Cognitive Enhancement Research

Institute (http://www.ceri.com) and a co-author of the 1993 book Smart Drugs

II. Steve's expertise is the use of generic substances (foods, dietary

supplements and patent-expired pharmaceuticals) to treat both "normal"

age-related mental decline (e.g., "senior moments" or chronic "brain fog")

and overt cognitive diseases (e.g., Down's syndrome and Alzheimer's

disease). In 2002, he invented the first of a series of vector-directional

polymers with nanostructural self-assembly capabilities, which he is now

developing in two startups. He will contrast the divergent developmental

challenges with generic vs. proprietary technologies to explain why both

leave viable solutions sitting unused on the shelf.



Tom Nufert is a co-founding partner with Steve Fowkes in Nanopolymer Systems

(http://nanopolymersystems.com) and ThioCell (the nanostructured-battery

company). Tom was a co-founder of Array BioSciences, which developed a

universal spit-on-a-chip bioanalytical system (merging chemistry, biology

and physics) and TRC Corporation, which developed chromium-based

pharmaceutical treatments for insulin resistance (syndrome X). He has

extensive knowledge of self-care treatments for a variety of chronic

degenerative conditions ranging from the near-universal-in-America insulin

resistance to the #2 and #3 causes of death‹heart disease and cancer.











[Non-text portions of this message have been removed]

Three perspectives on technology evolution

Richard Hamilton Gibbs, Steven W. Fowkes, Tom Nufert



When:    Tuesday, October 14th, 6:30 - 9:00 pm 

Where:   Fenwick & West, 801 California St., Mountain View, CA 

RSVP:     http://www.jhtc.org



Regular Admission: $10    

Student Admission: $5  (ID required)

Members Admission: Included (Join at http://jhtc.org)



Agenda

6:30 - 7:00:  Networking, schmoozing and eating - Bring your job postings,

business cards and resumes!

7:00 - 7:10:  Welcome, committee news and other group business

7:10 - 8:30:  Presentation and Discussion with our featured guests

8:30 - 9:00:  Informal discussions and networking with our guests and each

other



A light meal and soft drinks will be provided



About the Speakers

Richard Hamilton Gibbs is an entrepreneur in the computer, computer

peripheral, media and home entertainment markets currently researching how

technological advances are affecting distribution models for music and

movies and how adherence to traditional models are damaging the

profitability of mainstream entertainment businesses, sabotaging revenues

for artists, and alienating consumers based on competition between

proprietary and non-proprietary platforms.



Steven W. Fowkes is the Director of the Cognitive Enhancement Research

Institute (http://www.ceri.com) and a co-author of the 1993 book Smart Drugs

II. Steve's expertise is the use of generic substances (foods, dietary

supplements and patent-expired pharmaceuticals) to treat both "normal"

age-related mental decline (e.g., "senior moments" or chronic "brain fog")

and overt cognitive diseases (e.g., Down's syndrome and Alzheimer's

disease). In 2002, he invented the first of a series of vector-directional

polymers with nanostructural self-assembly capabilities, which he is now

developing in two startups. He will contrast the divergent developmental

challenges with generic vs. proprietary technologies to explain why both

leave viable solutions sitting unused on the shelf.



Tom Nufert is a co-founding partner with Steve Fowkes in Nanopolymer Systems

(http://nanopolymersystems.com) and ThioCell (the nanostructured-battery

company). Tom was a co-founder of Array BioSciences, which developed a

universal spit-on-a-chip bioanalytical system (merging chemistry, biology

and physics) and TRC Corporation, which developed chromium-based

pharmaceutical treatments for insulin resistance (syndrome X). He has

extensive knowledge of self-care treatments for a variety of chronic

degenerative conditions ranging from the near-universal-in-America insulin

resistance to the #2 and #3 causes of death‹heart disease and cancer.











[Non-text portions of this message have been removed]